COVID Cloud

Consortium will expand development of a software platform for genomics and health data and apply it to COVID-19. The $5.1M project, called COVID Cloud, aims to increase Canada’s capacity to harness exponentially growing volumes of genomics and biomedical data to advance precision health.

Read More

BioSymetrics Collaborates with Janssen and Sema4 to Predict the Onset of COVID-19

As part of the collaboration, the parties will use BioSymetrics’ Contingent-AI™ engine across several projects to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course, and identify markers for clinical phenotype and severity of disease.

Read More

Uniting Against COVID-19

Already working with clinicians, leveraging international collaborations to put prediction platforms in place, and re-investigating our drug lead pipeline, BioSymetrics will pursue any collaboration to have a positive impact against COVID and support the heroes working tirelessly in the hospitals and clinics around the world.

Read More

FDA developing new rules for artificial intelligence in medicine

It’s very encouraging to see the FDA showing forward thinking when it comes to AI/ML-based diagnostics. Even the best model can be outdated quickly given the changing data landscape, making frameworks like Augusta that allow for model refinement and evolution to be crucial. We welcome this mindset as we work with our partners to build more interpretable and more adaptable diagnostic models.

FDA developing new rules for artificial intelligence in medicine